Tycel Phillips, MD: Update on Novel BTK Inhibitor for Marginal Zone Lymphoma

Posted: Tuesday, February 1, 2022

Tycel Phillips, MD, of the Rogel Cancer Center, University of Michigan, discusses what the phase II results of the CITADEL-204 study could mean for BTK inhibitor–naive patients with marginal zone lymphoma, who appeared to benefit from monotherapy with parsaclisib. This second-generation agent could have advantages over current therapies and may be a potential treatment option for those with relapsed or refractory disease.

---